Agios Pharmaceuticals, Inc. (AGIO) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Agios Pharmaceuticals, Inc. (AGIO) quarterly earnings & revenue
Agios Pharmaceuticals, Inc. (AGIO) reported revenue of $20.75M for Q1 2026, up 137.7% year-over-year, with net income of $-99.11M and diluted EPS of $-1.69.
Over the last four reported quarters, Agios Pharmaceuticals, Inc. generated $66.05M in revenue and $-422.60M in net income.
Agios Pharmaceuticals, Inc.'s next earnings report is scheduled for July 30, 2026; analysts estimate EPS of $-1.67.
Agios Pharmaceuticals, Inc. quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q1 2026 | $20.75M | +137.7% | $-99.11M | $-1.69 |
| Q4 2025 | $19.97M | +86.1% | $-108.04M | $-1.85 |
| Q3 2025 | $12.88M | +43.7% | $-103.43M | $-1.78 |
| Q2 2025 | $12.46M | +44.6% | $-112.02M | $-1.93 |
| Q1 2025 | $8.73M | +6.6% | $-89.29M | $-1.55 |
| Q4 2024 | $10.73M | +51.1% | $-96.52M | $-1.69 |
| Q3 2024 | $8.96M | +21.2% | $947.91M | $16.22 |
| Q2 2024 | $8.62M | +28.4% | $-96.12M | $-1.69 |
Agios Pharmaceuticals, Inc. (AGIO) — frequently asked questions
When does Agios Pharmaceuticals, Inc. (AGIO) report earnings next?
Agios Pharmaceuticals, Inc. is expected to report earnings on July 30, 2026. Analysts estimate EPS of $-1.67.
What was AGIO's revenue last quarter?
Agios Pharmaceuticals, Inc. reported revenue of $20.75M in Q1 2026, up 137.7% from the same quarter a year earlier.
What was AGIO's EPS last quarter?
Agios Pharmaceuticals, Inc. reported diluted EPS of $-1.69 in Q1 2026.
Is Agios Pharmaceuticals, Inc. profitable?
Agios Pharmaceuticals, Inc. is currently not profitable, with $-422.60M in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)